A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants

NCT00756600 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 643

Last updated 2020-04-29

Study results available
· View outcomes & findings →

Summary

The primary purpose of the GAS study is to determine whether different types of anesthesia (Regional versus General) given to 720 infants undergoing inguinal hernia repair results in equivalent neurodevelopmental outcomes. The study also aims to describe the incidence of apnea in the post-operative period after both regional and general anesthesia for inguinal hernia repair in infants. This study is important as it will provide the greatest evidence for safety or toxicity of general anesthesia for human infants.

Conditions

  • Inguinal Hernia

Interventions

DRUG

Regional Anesthesia

Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.

DRUG

General Anesthesia

Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.

Sponsors & Collaborators

  • Royal Children's Hospital

    collaborator OTHER
  • Royal Hospital for Sick Children

    collaborator OTHER
  • Murdoch Childrens Research Institute

    collaborator OTHER
  • Food and Drug Administration (FDA)

    collaborator FED
  • Boston Children's Hospital

    lead OTHER

Principal Investigators

  • Andrew Davidson, MD · Royal Children's Hospital, Victoria, Australia

  • Mary Ellen McCann, MD · Children's Hospital Boston, United States of America

  • Neil Morton, MD · Royal Hospital for Sick Children, Glasgow, United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Max Age
60 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-23
Primary Completion
2018-06-30
Completion
2018-06-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Italy
  • Netherlands
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00756600 on ClinicalTrials.gov